Regencell Bioscience Holdings Limited (NASDAQ:RGC) Sees Significant Drop in Short Interest

Regencell Bioscience Holdings Limited (NASDAQ:RGC) was the target of a significant decline in short interest during the month of February. As of February 13th, there was short interest totaling 670,710 shares, a decline of 13.3% from the January 29th total of 773,634 shares. Based on an average daily volume of 167,394 shares, the short-interest ratio is currently 4.0 days. Approximately 0.1% of the shares of the company are sold short. Approximately 0.1% of the shares of the company are sold short. Based on an average daily volume of 167,394 shares, the short-interest ratio is currently 4.0 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Regencell Bioscience in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

Regencell Bioscience Price Performance

NASDAQ:RGC traded up $0.70 during mid-day trading on Wednesday, hitting $24.69. 44,765 shares of the stock traded hands, compared to its average volume of 535,551. Regencell Bioscience has a 12-month low of $0.11 and a 12-month high of $83.60. The business’s 50-day moving average price is $28.98 and its 200 day moving average price is $19.98.

Institutional Trading of Regencell Bioscience

A number of hedge funds have recently bought and sold shares of RGC. Seven Fleet Capital Management LP purchased a new stake in shares of Regencell Bioscience in the 4th quarter valued at $92,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Regencell Bioscience in the second quarter valued at about $222,000. Hudson Bay Capital Management LP purchased a new stake in shares of Regencell Bioscience during the fourth quarter worth about $275,000. Vident Advisory LLC grew its position in shares of Regencell Bioscience by 65.7% in the 4th quarter. Vident Advisory LLC now owns 29,934 shares of the company’s stock worth $629,000 after buying an additional 11,866 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Regencell Bioscience in the third quarter worth $598,000. Institutional investors own 0.13% of the company’s stock.

About Regencell Bioscience

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.